The Patented Uses of D-Ribose in Cardiovascular Diseases
| Autor: | Linda M. Shecterle, John A. St. Cyr, Kathleen R. Terry |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Myocardial ischemia Ribose Drug Evaluation Preclinical Myocardial Ischemia Ischemia Disease Bioinformatics Patents as Topic Adenosine Triphosphate Drug Discovery medicine Animals Humans Pharmacology (medical) In patient Heart Failure Clinical Trials as Topic business.industry Myocardium medicine.disease Clinical trial Cardiovascular Diseases Heart failure Dietary Supplements Physical therapy Animal studies Energy Metabolism Cardiology and Cardiovascular Medicine Ischemic heart business |
| Zdroj: | Recent Patents on Cardiovascular Drug Discovery. 5:138-142 |
| ISSN: | 1574-8901 |
| Popis: | Cardiovascular diseases account for more deaths worldwide than any other illness. Myocardial ischemia, a common finding in cardiovascular diseases, lowers cellular energy levels, which affects a cell's integrity and function. Pre-clinical animal studies have reported lower cellular energy levels with an associated decreased function following myocardial ischemia. Recently, scientists have reported that the failing heart is energy starved and yet no pharmaceuticals have been able to address this issue with satisfactory results. Over decades, researchers have explored the use of various metabolites to replenish deficient cellular energy levels following induced ischemia with mixed results. However, D-ribose, a natural occurring carbohydrate, has demonstrated significant enhancing abilities in replenishing deficient cellular energy levels following myocardial ischemia, as well as improving depressed function in numerous animal investigations. Subsequent clinical trials have further substantiated these benefits of D-ribose in patients afflicted with ischemic cardiovascular disease and those carrying the diagnosis of congestive heart failure. The future of effective therapies for ischemic heart disease and congestive heart failure must strongly consider novel pharmaceuticals directed at replenishing cellular energy levels. Intellectual property and the represented patents in this paper emphasize the use of D-ribose for its cellular energy enhancing potential, reflected in both objective and subjective clinical improvements; therefore, substantiating its value in patients with ischemic cardiovascular diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|